| Dr Kathryn Jeanne-henault Heaphy, MD | |
|
22 Bramhall St, Portland, ME 04102 | |
| (207) 662-0111 | |
| (207) 956-6676 |
| Full Name | Dr Kathryn Jeanne-henault Heaphy |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 11 Years |
| Location | 22 Bramhall St, Portland, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104262013 | NPI | - | NPPES |
| 1104262013 | Medicaid | ME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 274816 (Massachusetts) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | MD22806 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Hospital Of Central Connecticut | New britain, CT | Hospital |
| Midstate Medical Center | Meriden, CT | Hospital |
| William W Backus Hospital | Norwich, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Meriden Imaging Center Inc | 4385683556 | 49 |
| Midstate Radiology Associates, Llc | 4880593565 | 73 |
News Archive
PolyMedix, Inc. (www.polymedix.com), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, provided an overview of its 2010 clinical milestones in a presentation by President & C.E.O., Nicholas Landekic at the 2010 BIO CEO & Investor Conference.
Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.
Odors have a way of connecting us with moments buried deep in our past. Maybe it is a whiff of your grandmother's perfume that transports you back decades. With that single breath, you are suddenly in her living room, listening as the adults banter about politics.
It is estimated that during a heart attack, one billion cells in the heart are lost. In the wake of the heart attack, the lost tissue is replaced by scar tissue, which can lead to heart failure, arrhythmia and death. In a new study, researchers from the University of Tsukuba have shown how cells in the scar tissue can be converted to heart muscle cells, effectively regenerating the injured heart.
Researchers suggest a possible cell-based therapy to stimulate lung development in fragile premature infants who suffer from a rare condition called Bronchopulmonary Dysplasia, which in the most severe cases can lead to lifelong breathing problems and even death.
› Verified 5 days ago
| Entity Name | Starling Physicians, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467537290 PECOS PAC ID: 7517863749 Enrollment ID: O20031209000877 |
News Archive
PolyMedix, Inc. (www.polymedix.com), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, provided an overview of its 2010 clinical milestones in a presentation by President & C.E.O., Nicholas Landekic at the 2010 BIO CEO & Investor Conference.
Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.
Odors have a way of connecting us with moments buried deep in our past. Maybe it is a whiff of your grandmother's perfume that transports you back decades. With that single breath, you are suddenly in her living room, listening as the adults banter about politics.
It is estimated that during a heart attack, one billion cells in the heart are lost. In the wake of the heart attack, the lost tissue is replaced by scar tissue, which can lead to heart failure, arrhythmia and death. In a new study, researchers from the University of Tsukuba have shown how cells in the scar tissue can be converted to heart muscle cells, effectively regenerating the injured heart.
Researchers suggest a possible cell-based therapy to stimulate lung development in fragile premature infants who suffer from a rare condition called Bronchopulmonary Dysplasia, which in the most severe cases can lead to lifelong breathing problems and even death.
› Verified 5 days ago
| Entity Name | Midstate Radiology Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578518999 PECOS PAC ID: 4880593565 Enrollment ID: O20031231000543 |
News Archive
PolyMedix, Inc. (www.polymedix.com), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, provided an overview of its 2010 clinical milestones in a presentation by President & C.E.O., Nicholas Landekic at the 2010 BIO CEO & Investor Conference.
Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.
Odors have a way of connecting us with moments buried deep in our past. Maybe it is a whiff of your grandmother's perfume that transports you back decades. With that single breath, you are suddenly in her living room, listening as the adults banter about politics.
It is estimated that during a heart attack, one billion cells in the heart are lost. In the wake of the heart attack, the lost tissue is replaced by scar tissue, which can lead to heart failure, arrhythmia and death. In a new study, researchers from the University of Tsukuba have shown how cells in the scar tissue can be converted to heart muscle cells, effectively regenerating the injured heart.
Researchers suggest a possible cell-based therapy to stimulate lung development in fragile premature infants who suffer from a rare condition called Bronchopulmonary Dysplasia, which in the most severe cases can lead to lifelong breathing problems and even death.
› Verified 5 days ago
| Entity Name | Diagnostic Imaging Services Of Ct Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093760431 PECOS PAC ID: 3577465111 Enrollment ID: O20040123000288 |
News Archive
PolyMedix, Inc. (www.polymedix.com), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, provided an overview of its 2010 clinical milestones in a presentation by President & C.E.O., Nicholas Landekic at the 2010 BIO CEO & Investor Conference.
Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.
Odors have a way of connecting us with moments buried deep in our past. Maybe it is a whiff of your grandmother's perfume that transports you back decades. With that single breath, you are suddenly in her living room, listening as the adults banter about politics.
It is estimated that during a heart attack, one billion cells in the heart are lost. In the wake of the heart attack, the lost tissue is replaced by scar tissue, which can lead to heart failure, arrhythmia and death. In a new study, researchers from the University of Tsukuba have shown how cells in the scar tissue can be converted to heart muscle cells, effectively regenerating the injured heart.
Researchers suggest a possible cell-based therapy to stimulate lung development in fragile premature infants who suffer from a rare condition called Bronchopulmonary Dysplasia, which in the most severe cases can lead to lifelong breathing problems and even death.
› Verified 5 days ago
| Entity Name | Hospital For Special Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477534089 PECOS PAC ID: 7810985637 Enrollment ID: O20040506000578 |
News Archive
PolyMedix, Inc. (www.polymedix.com), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, provided an overview of its 2010 clinical milestones in a presentation by President & C.E.O., Nicholas Landekic at the 2010 BIO CEO & Investor Conference.
Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.
Odors have a way of connecting us with moments buried deep in our past. Maybe it is a whiff of your grandmother's perfume that transports you back decades. With that single breath, you are suddenly in her living room, listening as the adults banter about politics.
It is estimated that during a heart attack, one billion cells in the heart are lost. In the wake of the heart attack, the lost tissue is replaced by scar tissue, which can lead to heart failure, arrhythmia and death. In a new study, researchers from the University of Tsukuba have shown how cells in the scar tissue can be converted to heart muscle cells, effectively regenerating the injured heart.
Researchers suggest a possible cell-based therapy to stimulate lung development in fragile premature infants who suffer from a rare condition called Bronchopulmonary Dysplasia, which in the most severe cases can lead to lifelong breathing problems and even death.
› Verified 5 days ago
| Entity Name | Meriden Imaging Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508812561 PECOS PAC ID: 4385683556 Enrollment ID: O20050427000621 |
News Archive
PolyMedix, Inc. (www.polymedix.com), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, provided an overview of its 2010 clinical milestones in a presentation by President & C.E.O., Nicholas Landekic at the 2010 BIO CEO & Investor Conference.
Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.
Odors have a way of connecting us with moments buried deep in our past. Maybe it is a whiff of your grandmother's perfume that transports you back decades. With that single breath, you are suddenly in her living room, listening as the adults banter about politics.
It is estimated that during a heart attack, one billion cells in the heart are lost. In the wake of the heart attack, the lost tissue is replaced by scar tissue, which can lead to heart failure, arrhythmia and death. In a new study, researchers from the University of Tsukuba have shown how cells in the scar tissue can be converted to heart muscle cells, effectively regenerating the injured heart.
Researchers suggest a possible cell-based therapy to stimulate lung development in fragile premature infants who suffer from a rare condition called Bronchopulmonary Dysplasia, which in the most severe cases can lead to lifelong breathing problems and even death.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kathryn Jeanne-henault Heaphy, MD 324 Gannett Dr Ste 200, South Portland, ME 04106-3266 Ph: (207) 482-7861 | Dr Kathryn Jeanne-henault Heaphy, MD 22 Bramhall St, Portland, ME 04102 Ph: (207) 662-0111 |
News Archive
PolyMedix, Inc. (www.polymedix.com), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, provided an overview of its 2010 clinical milestones in a presentation by President & C.E.O., Nicholas Landekic at the 2010 BIO CEO & Investor Conference.
Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.
Odors have a way of connecting us with moments buried deep in our past. Maybe it is a whiff of your grandmother's perfume that transports you back decades. With that single breath, you are suddenly in her living room, listening as the adults banter about politics.
It is estimated that during a heart attack, one billion cells in the heart are lost. In the wake of the heart attack, the lost tissue is replaced by scar tissue, which can lead to heart failure, arrhythmia and death. In a new study, researchers from the University of Tsukuba have shown how cells in the scar tissue can be converted to heart muscle cells, effectively regenerating the injured heart.
Researchers suggest a possible cell-based therapy to stimulate lung development in fragile premature infants who suffer from a rare condition called Bronchopulmonary Dysplasia, which in the most severe cases can lead to lifelong breathing problems and even death.
› Verified 5 days ago
Michael O'malley Quinn, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-2571 | |
Elena Leah Resnick, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-2571 | |
Matthew D Ralston, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-2571 | |
Jerald Christopher Kuhn, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 144 State St, Portland, ME 04101 Phone: 207-879-3000 | |
Whitney Beeler, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-4735 Fax: 207-662-6388 | |
David Russell Langdon, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 144 State St, Portland, ME 04101 Phone: 207-879-3000 | |
Ethan M Dobrow, MD Radiology Medicare: Medicare Enrolled Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-2526 |